Sugi Predict

Sugi Predict / Compounds / Cholesterol

Cholesterol

Cholesterol

SCHEMBL454869

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C.OCCO

nearest known ligand 0.94

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OSBP P22059 6/20 0.94
▸ RORC P51449 5/20 0.94
▸ OSBP2 Q969R2 3/20 0.94
▸ USP2 O75604 1/20 0.94
▸ LMNA P02545 1/20 0.94
▸ ABCB1 P08183 1/20 0.94
▸ CYP46A1 Q9Y6A2 1/20 0.94
▸ GRIN1 Q05586 6/20 0.87
▸ GRIN2A Q12879 6/20 0.87
▸ NR1H3 Q13133 7/20 0.82
▸ DHCR24 Q15392 1/20 0.76
▸ CRYAB P02511 1/20 0.76
▸ HMGCR P04035 1/20 0.76
▸ ITGB3 P05106 1/20 0.76
▸ ITGAV P06756 1/20 0.76
▸ SREBF2 Q12772 1/20 0.76
▸ NPC1L1 Q9UHC9 1/20 0.76
▸ GRIN2B Q13224 5/20 0.75
▸ EPHA2 P29317 1/20 0.72
▸ NR1H2 P55055 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cholesterol SCHEMBL454868 1.00 OSBP (0.94) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21681224 1.00 OSBP (0.94) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21707472 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21447271 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL22095727 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL23761109 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL22225160 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL23579652 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL23365796 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA
Cholesterol SCHEMBL21445079 0.97 OSBP (1.00) OSBPRORCOSBP2USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4106828-A1 POLYMER-ENCAPSULATED DRUG PARTICLES GIE Medical, Inc. (US) 2022-12-28 — — EP claimed
WO-2019204451-A1 ENHANCED LIPID NANOPARTICLE DRUG DELIVERY USING A NEGATIVELY CHARGED POLYMER CARNEGIE MELLON UNIVERSITY (US) 2019-10-24 — — WO claimed
CN-106497931-B A kind of ssDNA aptamers for Her3ECD and its application in diagnoses and treatment HER3 related disease 中国人民解放军军事科学院军事医学研究院 2019-07-12 — — CN claimed
EP-2662389-B1 METHOD FOR PREPARING ANTIGEN TO OBTAIN ANTIHYDROPHOBIC PEPTIDE ANTIBODY TOAGOSEI CO LTD (JP) 2019-03-13 — — EP claimed
US-9506933-B2 Method of preparing antigen for acquiring anti-hydrophobic peptide antibody TOAGOSEI CO., LTD. (JP) 2016-11-29 — — US claimed
WO-2015148567-A1 MOLECULAR ADAPTER FOR CAPTURE AND MANIPULATION OF TRANSFER RNA BERNICK DAVID L (US) 2015-10-01 — — WO claimed
US-20140072592-A1 METHOD OF PREPARING ANTIGEN FOR ACQUIRING ANTI-HYDROPHOBIC PEPTIDE ANTIBODY SEIKO EPSON CORPORATION (JP) 2014-03-13 — — US claimed
EP-2662389-A1 METHOD FOR PREPARING ANTIGEN TO OBTAIN ANTIHYDROPHOBIC PEPTIDE ANTIBODY Toagosei Co., Ltd (JP) 2013-11-13 — — EP claimed
EP-1761551-B1 GEMCITABINE DERIVATIVES NANOPARTICLES CENTRE NAT RECH SCIENT (FR) 2011-08-10 — — EP claimed
US-7704972-B2 Gemcitabine derivatives nanoparticles CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2010-04-27 — — US claimed
US-20090130214-A1 Gemcitabine derivatives nanoparticles Universite Paris-Saclay (FR) 2009-05-21 — — US claimed
EP-1761551-A1 GEMCITABINE DERIVATIVES NANOPARTICLES The Centre National de la Recherche Scientifique (FR) 2007-03-14 — — EP claimed
WO-2006090029-A1 GEMCITABINE DERIVATIVES NANOPARTICLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2006-08-31 — — WO claimed
CN-117338948-A ACE2 specific binding peptide modified drug delivery system and preparation method and application thereof 四川大学 2024-01-05 — — CN disclosed
WO-2023091475-A1 METHOD FOR TREATMENT OF AIRWAY STRICTURE OR STENOSIS AIRIVER MEDICAL, INC. (US) 2023-05-25 — — WO disclosed
US-20230086736-A1 MICROEMULSION-BASED VACCINE DELIVERY SYSTEM, PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN UNIVERSITY (CN) 2023-03-23 — — US disclosed
US-20060240554-A1 Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules SIRNA THERAPEUTICS, INC. (US) 2006-10-26 — — US disclosed
WO-2006090029-A1 GEMCITABINE DERIVATIVES NANOPARTICLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2006-08-31 — — WO disclosed
EP-0636363-B1 Drug delivery system TERUMO CORP (JP) 2001-05-23 — — EP disclosed
EP-0636363-A2 Drug delivery system TERUMO KABUSHIKI KAISHA (JP) 1995-02-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140072592-A1 METHOD OF PREPARING ANTIGEN FOR ACQUIRING ANTI-HYDROPHOBIC PEPTIDE ANTIBODY CD44, TAP1, MICA OSBP 2500/4885RORC 4421/4885OSBP2 1303/4885
US-20060240554-A1 Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules PHAX, CETP, LIPC OSBP 1462/4885RORC 448/4885OSBP2 1919/4885
US-20090130214-A1 Gemcitabine derivatives nanoparticles KRAS, H1-3, MCL1 OSBP 4804/4885RORC 2373/4885OSBP2 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.